Efficacy of Dextromethorphan-Bupropion Versus SSRIs in the Treatment of Major Depressive Disorder: A Randomized Controlled Trial
Efficacy of Dextromethorphan-Bupropion Versus SSRIs in the Treatment of Major Depressive Disorder: A Randomized Controlled Trial
The study aims to compare the antidepressant effects of a dextromethorphan-bupropion combination versus standard SSRI therapy in adult patients with major depressive disorder. Participants will be randomized into two groups: one receiving dextromethorphan-bupropion and the other receiving an SSRI (e.g., sertraline or escitalopram). Treatment will last for 6 weeks, with assessments at baseline and study completion. The primary outcome will be the remission rate measured by a validated depression rating scale. Secondary outcomes include change in depressive symptoms severity and safety/tolerability measures.
Inclusion Criteria:
Diagnosed with major depressive disorder (MDD) per DSM-5 criteria.
Baseline depression score indicating moderate to severe depression
Ability to provide informed consent
Willing to comply with study requirements
Exclusion Criteria:
History of bipolar disorder, schizophrenia, or other psychotic disorders
Current substance use disorder (within past 6 months)
Active suicidal ideation requiring urgent intervention
Pregnancy or breastfeeding
Known hypersensitivity to study medications